Mangoceuticals, Inc. (MGRX)

Mangoceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	0.47	0.62	0.73	0.01
Revenue Growth (YoY)	-38.16%	-15.81%	8083.16%	-
Cost of Revenue	0.18	0.24	0.3	0
Gross Profit	0.28	0.38	0.43	0
Selling, General & Admin	19.63	8.35	9.65	2
Depreciation & Amortization Expenses	-	0.72	-	-
Total Operating Expenses	19.63	9.07	9.65	2
Operating Income	-19.34	-8.69	-9.22	-1.99
Interest Expense	-0.1	-0.01	0.01	-0.01
Other Non-Operating Income (Expense)	-0.13	-	-	-
Total Non-Operating Income (Expense)	-0.22	-0.01	0.01	-0.01
Pretax Income	-19.82	-8.71	-9.21	-2
Net Income	-27.73	-8.71	-9.21	-2
Minority Interest in Earnings	-0	-0	-	-
Net Income Attributable to Preferred Dividends	-0.29	-	-	-
Net Income to Common	-27.73	-8.71	-9.21	-2
Shares Outstanding (Basic)	7	2	1	1
Shares Outstanding (Diluted)	7	2	1	1
Shares Change (YoY)	332.51%	84.23%	49.22%	-
EPS (Basic)	-3.11	-4.84	-8.58	-2.85
EPS (Diluted)	-3.11	-4.84	-8.58	-2.85
Free Cash Flow	-5.85	-4.86	-7	-1.39
Free Cash Flow Per Share	-0.82	-2.46	-6.52	-1.93
Gross Margin	50.50%	61.70%	58.99%	54.26%
Operating Margin	-4152.75%	-1411.58%	-1260.28%	-22279.70%
Profit Margin	-4245.52%	-1413.80%	-1259.40%	-22352.11%
FCF Margin	-1253.46%	-789.74%	-957.07%	-15545.59%
EBITDA	-17.39	-7.96	-9.19	-1.99
EBITDA Margin	-3725.02%	-1292.81%	-1256.88%	-22236.48%
EBIT	-19.34	-8.69	-9.22	-1.99
EBIT Margin	-4152.75%	-1411.58%	-1260.28%	-22279.70%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q